The ponatinib and imatinib groups had similar rates of treatment-emergent adverse events, including grade 3 to grade 4 (90% vs. 93%) and grade 5 (5% each) events.

Transaminitis doesn’t always present with symptoms, so a blood test is required to diagnose it. (Photo Credit: Science Photo Library/Getty Images) Juan Pablo Arab, MD, associate professor of ...

In interim analysis results presented in JAMA, the team stated that overall, ponatinib had superior efficacy to imatinib, and similar safety. 1 Given those results, the FDA granted ponatinib ...

Opens in a new tab or window In the first randomized comparison of targeted agents for acute lymphoblastic leukemia (ALL), ponatinib (Iclusig) prevailed over imatinib for untreated Philadelphia ...

Ponatinib plus chemotherapy received accelerated FDA approval for newly-diagnosed Ph+ ALL, showing significant efficacy in the PhALLCON trial with 30% achieving MRD-negative CR. Treatment ...

Transaminitis, or hypertransaminasemia, refers to unusually high levels of a family of enzymes called transaminases. Possible causes include non-alcohol-related fatty liver disease (NAFLD) and ...

Researchers have discovered the mechanisms by which the chemotherapy drug ponatinib harms the heart. The findings highlight how ponatinib (Iclusig, Takeda) — one of three drugs approved in the ...

Findings showed 30% of patients in the ponatinib arm achieved MRD-negative complete response rate at the end of the induction phase vs 12% of those in the imatinib arm. The Food and Drug ...

Learn everything you need to know about Ponatinib-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions ...